Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Emily Miao, PharmD"'
Autor:
Brandon S. Imber, MD, MA, Ryka Sehgal, MD, Rachel Saganty, MD, Anne S. Reiner, MPH, A. Turan Ilica, MD, Emily Miao, PharmD, Bob T. Li, MD, Gregory J. Riely, MD, Helena A. Yu, MD, Katherine S. Panageas, DrPH, Robert J. Young, MD, Luke R.G. Pike, MD, DPhil, Nelson S. Moss, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100607- (2023)
Introduction: Patients with EGFR-mutant NSCLC have a high incidence of brain metastases. The EGFR-directed tyrosine kinase inhibitor osimertinib has intracranial activity, making the role of local central nervous system (CNS)-directed therapies, such
Externí odkaz:
https://doaj.org/article/eb50687c81bc4fa09768c4beb4a3d785
Autor:
Yu Y; Yao Yu, MD, Emily Miao, PharmD, and Luke R.G. Pike, MD, DPhil, Memorial Sloan Kettering Cancer Center, New York, NY., Miao E; Yao Yu, MD, Emily Miao, PharmD, and Luke R.G. Pike, MD, DPhil, Memorial Sloan Kettering Cancer Center, New York, NY., Pike LRG; Yao Yu, MD, Emily Miao, PharmD, and Luke R.G. Pike, MD, DPhil, Memorial Sloan Kettering Cancer Center, New York, NY.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jun 10; Vol. 42 (17), pp. 2107-2108. Date of Electronic Publication: 2024 Apr 03.